CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1

    February 2025 in “ PubMed
    Hui Jin, Zongyang Li, Xinwen Li, Qiongqiong Xu, Beizhong Chen, Song Shan, Desi Pan, Peng Hu, Shengjian Huang
    TLDR CS12192 effectively treats alopecia areata with better safety than current options.
    The study investigates the efficacy and safety of CS12192, a selective JAK3 inhibitor that also partially inhibits JAK1 and TBK1, in treating alopecia areata (AA) using a C3H/HeJ skin-transplanted AA mouse model. CS12192 demonstrated a dose-dependent ability to reverse hair growth inhibition, with high doses showing effectiveness comparable to baricitinib but with improved safety. Both CS12192 and baricitinib significantly reduced immune cell infiltration, particularly CD8+ T cells, in the skin of AA mice. Mechanistic analysis using CyTOF and RNA-seq revealed similarities in how both compounds regulate AA-related immune cells and signaling pathways. CS12192 shows promise as a novel treatment for AA with potentially better safety profiles.
    Discuss this study in the Community →

    Related Community Posts Join

    0 / 0 results
    — no results

    Related Research

    2 / 2 results